Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic EGFR CLIA Test

Transgenomic has launched its new CLIA laboratory-based test for EGFR mutation detection in cancer patients using proprietary MX-ICP technology with any sample type.

The test is for EGFR exon 20 T790M mutations that affect the utility of tyrosine kinase inhibitor drugs for non-small cell lung cancer and EGFR exon 12 S492R mutations that signify resistance to the widely-prescribed drug cetuximab in coloretal cancer patients. 

The test can use tissue, plasma, fine needle aspiration, bronchoscopy, cytology, and other bodily fluid samples. Actionable results will be available in seven to 10 working days, Transgenomic said.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.